Quick Answer
Regen BioPharma Inc reported Operating Income of -$338.5 thousand for fiscal year 2025.
Regen BioPharma Inc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$338.5K | +18.9% |
| 2024 | -$417.2K | +39.3% |
| 2023 | -$687.0K | -102.3% |
| 2022 | -$339.6K | -69.2% |
| 2021 | -$200.8K | +4.1% |
| 2020 | -$209.3K | +72.3% |
| 2019 | -$756.8K | +46.9% |
| 2018 | -$1.43M | +43.2% |
| 2017 | -$2.51M | +15.1% |
| 2016 | -$2.96M | -49.4% |
| 2015 | -$1.98M | -180.2% |
| 2014 | -$706.4K | -120.8% |
| 2013 | -$319.8K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$551.6K | -798.7% | -1253.5% |
| June 30, 2025 | -$40.8K | +62.3% | +64.0% |
| March 31, 2025 | -$113.3K | -12.1% | -84.7% |
| December 31, 2024 | -$61.4K | +50.0% | +43.2% |
| June 30, 2024 | -$108.0K | -26.8% | -6.8% |
| March 31, 2024 | -$101.1K | -28.2% | +17.7% |
| December 31, 2023 | -$122.8K | +73.5% | -44.2% |
| June 30, 2023 | -$85.2K | -44.6% | -8.0% |
- Regen BioPharma Inc showed an increase of +18.9% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Regen BioPharma Inc’s operating income has declined by 5.8% (from -$319.8 thousand to -$338.5 thousand).
- The most recent figure is from Regen BioPharma Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: